Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data f...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lee, Stephanie J., Kukreja, Manisha, Wang, Tao, Giralt, Sergio A., Szer, Jeffrey, Arora, Mukta, Woolfrey, Ann E., Cervantes, Francisco, Champlin, Richard E., Gale, Robert Peter, Halter, Joerg, Keating, Armand, Marks, David I., McCarthy, Philip L., Olavarria, Eduardo, Stadtmauer, Edward A., Abecasis, Manuel, Gupta, Vikas, Khoury, H. Jean, George, Biju, Hale, Gregory A., Liesveld, Jane L., Rizzieri, David A., Antin, Joseph H., Bolwell, Brian J., Carabasi, Matthew H., Copelan, Edward, Ilhan, Osman, Litzow, Mark R., Schouten, Harold C., Zander, Axel R., Horowitz, Mary M., Maziarz, Richard T.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2008
Sujets:
Transplantation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2954751/
https://ncbi.nlm.nih.gov/pubmed/18664621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141689
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires